Cardiology Month in Review: December 2021
Each month, our editorial staff compiles a month in review highlighting the most popular content from the past month. December's month in review features new guidelines, FDA news, and more.
Editor's note: Clicking on a slide will redirect you to that article.
Top Stories from December 2021
- FDA Approves Twice-Yearly Inclisiran (Leqvio) for Lowering Cholesterol in ASCVD, HeFH
Announced on December 22, the approval of inclisiran (Leqvio) comes nearly a year after the original PDUFA date. With approval, inclisiran becomes the first and only siRNA therapy approved to lower LDL-C with twice-yearly dosing. - AHA Releases New Statement on Diagnosing, Managing Hypertensive Disorders of Pregnancy
Released on Dec. 15, the latest scientific statement from the American Heart Association provides a comprehensive overview of the available evidence on topics related to diagnosis, management, and pharmacotherapy for hypertension during pregnancy. - Noteworthy Cardiology Posters from the World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease
The Practical Cardiology editorial staff has compiled a list of 6 noteworthy posters related to cardiology from the Metabolic Institute of America's 19th annual World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease. - New Revascularization Guidelines Released by ACC, AHA, and SCAI
The ACC/AHA/SCAI 2021 guideline recommendations for coronary artery revascularization were released on December 9, which they hope will replace or retire recommendations from half a dozen previous guidelines. - American Heart Association Report Raises Alarm on Blood Pressure Increases During Pandemic
A report published in Circulation details per month increases in both systolic and diastolic blood pressure observed during the pandemic as compared with prepandemic periods.
